|
Kendle is a leading global clinical research organization providing the full range of early– to late–stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide.
As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.
Kendle has a 27-year history of serving customers, both large and small, and with a diversity of compounds, which means that our expertise spans every major therapeutic area. We have focused our therapeutic offerings on market needs and are already aligned with the top areas expected to represent 73 percent of worldwide drug sales through 2012: oncology/hematology, antibiotics/antivirals, cardiology, arthritis/inflammation, CNS and diabetes/metabolism.1
Our mission
To be the best-in-class provider of clinical development services to the biopharmaceutical industry through broad therapeutic and geographic expertise.
Our corporate imperatives
- Drive growth and profitability
- Focus on our customer and build our brand
- Maximize quality and increase capability
- Develop talent and reward performance
1Cowen & Company, "Therapeutic Categories Outlook," March 2008.
|
